natgillin/translations-raw huggingface dataset:
12 (3 X 4) pre-filled pens, + 12 (3 X 4) pen needles (multipack)
12 (3 x 4) napolnjenih peresnikov, + 12 (3 x 4) igel za peresnike (skupno pakiranje )
12 (3 X 4) pre-filled pens, + 12 (3 X 4) pen needles (multipack)
12 (3 x 4) napolnjenih peresnikov, + 12 (3 x 4) igel za peresnike (skupno pakiranje)
12 (3 x 4) pre-filled syringes (multipack)
12 (3 x 4) napolnjenih injekcijskih brizg (skupno pakiranje)
12 (4)
n=331
12 - 24 months) after primary immunization, prior to potential re-exposure to JEV.
12–24 mesecev) po primarnem cepljenju, in sicer pred morebitno ponovno izpostavljenostjo virusu japonskega encefalitisa.
12 - 24 months) after primary immunization, prior to potential re-exposure to JEV.
12–24 mesecev) po primarni imunizaciji, in sicer pred morebitno ponovno izpostavljenostjo virusu japonskega encefalitisa.
12 - 24 months) after the first dose of the recommended primary immunization.
12–24 mesecev) po prvem odmerku priporočene primarne imunizacije.
12 - Disconnect the syringe and the needle.
12 - Brizgo ločite od igle.
12 2051 Biatorbagy HUNGARY
2051 Biatorbagy MADŽARSKA
12 Adverse event identified from spontaneous post-marketing reporting with frequency estimated at the upper limit of the 95% confidence interval utilising the Olanzapine Integrated Database.
12Neželeni učinki, ugotovljeni pri spontanem poročanju v obdobju trženja s pogostostjo, ocenjeno na zgornjo mejo 95 % intervala zaupanja, določeno z uporabo integrirane baze podatkov za olanzapin.
12 Adverse event identified from spontaneous post-marketing reporting with frequency estimated at the upper limit of the 95% confidence interval utilising the Olanzapine Integrated Database.
Neželeni učinki, ugotovljeni pri spontanem poročanju v obdobju trženja s pogostostjo, ocenjeno na zgornjo mejo 95 % intervala zaupanja, določeno z uporabo integrirane baze podatkov za olanzapin.
12 applicators
12 aplikatorjev
12 ART-naïve HIV-1 infected paediatric patients aged from 12 to 17 years and weighing at least 40 kg who received PREZISTA tablets with low dose ritonavir once daily in combination with other antiretroviral agents (see section 5.1).
12 s HIV-1 okuženih pediatričnih bolnikov, ki nimajo izkušenj z ART, starih 12 do 17 let in s telesno maso najmanj 40 kg, ki so prejemali zdravilo PREZISTA filmsko obložene tablete skupaj z majhnim odmerkom ritonavirja enkrat na dan in z drugimi protiretrovirusnimi zdravili (glejte poglavje 5.1).
12 August 2010
12. avgust 2010
12 blisters (84 tablets)
12 pretisnih omotov (84 tablet)
12 bottles
12 steklenice
12 bottles 1.55 ml (8 sprays) per bottle
12 steklenic – 1,55 ml (8 vpihov) na steklenico
12 bottles – 1.55 ml (8 sprays) per bottle
12 steklenic – 1,55 ml (8 vpihov) na steklenico
12 capsules
12 kapsul
12 cartridges
12 vložki
12 cases [n = 2572 from pooled studies in young women]) against HPV 6-, 11-, 16-, and 18-related CIN 2/3, VIN 2/3, VaIN 2/3, and genital warts in women 16 to 26 years.
12 primerov [n = 2.572 iz združenih študij pri mladih ženskah]) proti s HPV 6, 11,16 in 18 povezane CIN 2/3, VIN 2/3, VaIN 2/3 in bradavice na spolovilih pri ženskah, starih 16 do 26 let.
12 clicks
klikov
12 hours after application
12 ur po nanosu
12 hours after dilution when stored at 2 °C-8 °C followed by 3 hours stored at 20 °C  5 °C (including infusion time).
12 ur po redčenju, če je bila raztopina shranjena pri temperaturi med 2 °C in 8 °C in nato 3 ure pri temperaturi 20 °C ± 5 °C (vključno s časom infuzije).
12 hours after dilution when stored at 2°C-8°C followed by 3 hours stored at 25°C ± 2°C (including infusion time).
do 12 ur po redčenju, če je bila raztopina shranjena pri temperaturi med 2 in 8 °C in nato 3 ure pri temperaturi 25 °C ± 2 °C (vključno s časom infuzije).
12 hours after the injection of enoxaparin sodium administration of protamine may not be necessary.
Če je od injiciranja natrijevega enoksaparinata minilo več kot 12 ur, morda protamina ne bo treba uporabiti.
12 hours after the injection of enoxaparin sodium administration of protamine may not be necessary.
Če je od injiciranja natrijevega enoksaparinata minilo več kot 12 ur, protamina morda ni treba uporabiti.
12 hours before or at least 4 hours after rilpivirine should be used.
H2-receptorjev, najmanj 12 ur pred ali vsaj 4 ure po odmerku rilpivirina.
12 hours or more after the time you usually take Tybost, then do not take the missed dose.
po 12 urah ali več od časa, ko običajno vzamete zdravilo Tybost, pozabljenega odmerka ne vzemite.
12 kg to less than 15 kg
od 12 kg do manj kot 15 kg
12 mg intrathecal, day 1
MTX 12 mg intratekalno, 1. dan
12 mg once daily
12 mg enkrat na dan
12 mg/day (24 ml/day).
12 mg/dan (24 ml/dan).
12 micrograms, respectively) were defined as co-primary endpoints in both 6-month pivotal Phase III studies to demonstrate the bronchodilator contributions of formoterol and aclidinium in Duaklir Genuair, respectively.
400 mikrogramov in formoterolom 12 mikrogramov) sta bili opredeljeni kot primarna cilja opazovanja v 6-mesečnih ključnih študijah 3. faze za dokazovanje bronhodilatornega učinka formoterola in aklidinija v zdravilu Duaklir Genuair.
12 month
12 mesecev
12 months
12 mesece v
12 months
za 12 mesecev
12 months (46% and 28%), 24 months (64% and 46%) , 36 months (67% and 55%), 48 months (73% and 60%) and 60 months (76% and 64%)were also consistent with the primary endpoint.
28%), 24 mesecih (64% oziroma 46%), 36 mesecih (67% in 55%), 48 mesecih (73% in 60%) in 60 mesecih (76% in 64%) prav tako konsistentni s primarnim opazovanim dogodkom.
12 months after
12 mesecev po cepljenju
12 months after 2nd dose
12 mesecev po 2. odmerku
12 months after booster
12 mesecev po poživitvenem odmerku
12 months after PDT (%)
12 mesecev po PDT (%)
12 months after the 1st dose N=559
12 mesecev po prvem odmerku n=559
12 months after the first revaccination
12 mesecev po prvi revakcinaciji
12 months and 24 months)
12 mesecev in 24 mesecev).
12 months PFS rate (95% CI) (%)
12-mesečna stopnja PBN (95 % IZ) (%)
12 months post-vaccination
12 mesecev po cepljenju
12 months thereafter and as clinically indicated.
12 mesecev zatem, ter kot je klinično indicirano.
12 months were 68.3 and 73.1, respectively).
12 mesecih sta bila 68,3 oziroma 73,1).
12 months with active treatment, the ACR response rates in leflunomide patients were 52.3 % (studies MN301/303), 50.5 % (study MN302) and 49.4 % (study US301), compared to 53.8 % (studies MN301/303) in sulphasalazine patients, 64.8 % (study MN302), and 43.9 % (study US301) in methotrexate patients.
Po 12 mesecih aktivnega zdravljenja so bili deleži odzivov po ACR pri bolnikih na leflunomidu 52, % (študiji MN301/303), 50,5% (študija MN302) in 49,4% (študija US301) v primerjavi s 53,8% (študiji MN301/303) pri bolnikih na sulfasalazinu ter 64,8% (študija
12 months) while on dasatinib or nilotinib.
12 mesecih) med uporabo dasatiniba ali nilotiniba.
12 months, with about 44% of patients achieving a normal HAQ score (less than 0.5).
Z zdravljenjem s 25 mg etanercepta so dosegli bistveno izboljšanje pri 12 mesecih - približno 44 % bolnikov je doseglo normalen rezultat HAQ (manj kot 0,5).
12 MU (120 µg/0.2 ml)
12 ME (120
12 needles for injection.
12 injekcijskih igel za injiciranje.
12 or 24 weeks
12 ali 24 tednov
12 orodispersible tablets
12 orodisperzibilnih tablet
12 patients are on-going in the study.
12 bolnikov še sodeluje v študiji.
12 pens (CLEARCLICK), 12 injection needles and 24 cleansing swabs 100 micrograms/0.5 ml
12 peresnikov (CLEARCLICK), 12 injekcijskih igel in 24 čistilnih tamponov 100 mikrogramov/0,5 ml
12 pens (CLEARCLICK), 12 injection needles and 24 cleansing swabs 150 micrograms/0.5 ml
12 peresnikov (CLEARCLICK), 12 injekcijskih igel in 24 čistilnih tamponov 150 mikrogramov/0,5 ml
12 pens (CLEARCLICK), 12 injection needles and 24 cleansing swabs 50 micrograms/0.5 ml
12 peresnikov (CLEARCLICK), 12 injekcijskih igel in 24 čistilnih tamponov 50 mikrogramov/0,5 ml
12 pens (CLEARCLICK), 12 injection needles and 24 cleansing swabs 80 micrograms/0.5 ml
12 peresnikov (CLEARCLICK), 12 injekcijskih igel in 24 čistilnih tamponov 80 mikrogramov/0,5 ml
12 pens + 12 injection needle
12 peresnikov +
12 pipettes
12 merilnih kapalk
12 pipettes
12 pipet
12 pre-filled pens
12 napolnjenih
12 pre-filled pens
12 napolnjenih injekcijskih peresnikov
12 pre-filled pens
12 v napolnjenem injekcijskem peresniku
12 pre-filled pens containing powder and solvent for solution for injection, 12 needles ("Push-On Needle"),
12 napolnjenih injekcijskih peresnikov s praškom in vehiklom za raztopino za injiciranje, 12 igel ("Igla na potisk"),
12 pre-filled syringes
12 napolnjena brizga
12 pre-filled syringes
12 napolnjenih injekcijskih brizg
12 pre-filled syringes of 1 ml solvent 12 stainless steel injection needles 12 vial adaptors
12 napolnjenih injekcijskih brizg z 1 ml vehikla 12 igel iz nerjavečega jekla
12 sachets
12 Blazinica
12 sachets
12 vrečic
12 single dose vials, 12 injection syringes of 1 mL, 12 injection needles and 12 cleansing swabs
12 vial z enkratnim odmerkom, 12 (1-mililitrskih) injekcijskih brizg, 12 injekcijskih igel in 12 čistilnih tamponov
12 single dose vials, 12 injection syringes of 2 mL, 12 injection needles and 12 cleansing swabs
12 vial z enkratnim odmerkom, 12 (2-mililitrskih) injekcijskih brizg, 12 injekcijskih igel in 12 čistilnih tamponov
12 single dose vials, 12 injection syringes, 12 injection needles and 12 cleansing swabs
12 vial z enkratnim odmerkom, 12 injekcijskih brizg, 12 injekcijskih igel in 12 čistilnih tamponov
12 spot-on applicators
12 aplikatorjev za kožni nanos
12 tablets
(PVdC/PVC/alu)
12 to 14 kg
12 do 14 kg
12 to 14 kg*
12 do 14 kg
12 to 17 years
12 do 17 let
12 to 23 months
od 12 do 23 mesecev
12 to < 18 years
12 do < 18 let
12 to < 18 years ETR
12 do < 18 let ETR N=60
12 to < 24 months
12 do < 24 mesecev
12 to <18 years (12, 17)
12 do < 18 let (12, 17)
12 to <18 years (N=8)
12 do <18 let (N=8)
12 tubes
12 tub
12 units are marked on the residual scale.
12 enot je označenih na merilu preostanka.
12 units are marked on the residual scale.
Oznako za 12 enot najdete na merilu preostanka.
12 units Residual scale
12 enot merilo preostanka
12 vials
12 vial
12 vials
12 viale
12 vials
ime
12 vials + 12 injection sets2
Izmišljeno
12 vials + 12 pre-filled syringes + 24
12 viale + 12 napolnjene brizge
12 vials + 72 injection syringes with attached needle + 144 cleansing swabs
12 vial + 72 injekcijskih
12 vials of 0.3[0.45; 0.7; 1] ml
12 vial z 0,3[0,45; 0,7; 1] ml
12 vials of powder
12 vial s praškom
12 vials of powder for solution for injection, 12 ampoules of solvent for injection, 12 injection syringes, 24 injection needles and 12 cleansing swabs.
12 vial praška za raztopino za injiciranje in 12 ampul vehikla za injiciranje, 12 injekcijskih brizg, 24 injekcijskih igel in 12 čistilnih tamponov.
12 vials of powder for solution for injection, 12 ampoules of solvent for parenteral use, 12 injection syringes, 24 injection needles and 12 cleansing swabs.
12 vial s praškom za raztopino za injiciranje, 12 ampul z vehiklom za parenteralno uporabo, 12 injekcijskih brizg, 24 injekcijskih igel in 12 čistilnih tamponov.
12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs
12 vial praška, 12 ampul vehikla, 12 injekcijskih brizg, 24 injekcijskih igel, 12 čistilnih tamponov
12 weeks
Preglednica 12.
12 weeks (n = 103)a
12 tednov (n = 103)a
12 weeks (n = 132)
12 tednov (n = 132)
12 weeks (n = 168)a
12 tednov (n = 168)a
12 weeks (n = 183)
12 tednov (n = 183)
12 weeks (n = 211)
12 tednov (n = 211)
12 weeks (n = 216)
12 tednov (n = 216)
12 weeks (n = 335)
12 tednov (n = 335)
12 weeks (n = 39)
12 tednov (n = 39)
12 weeks (n = 64)
12 tednov (n = 64)
12 weeks (n = 73)a
12 tednov (n = 73)a
12 weeks and were allowed to dose adjust to receive ustekinumab every 8 weeks.
Ustekinumab lahko poveča tveganje za nastanek okužb in vodi do reaktivacije latentnih okužb.
12 weeks for men and women without childbearing potential
12 tednov za moške in ženske, ki ne morejo zanositi
12 weeks N = 129†
24 (23%)a
12 weeks OLYSIO + sofosbuvir + ribavirin2
12 tednov OLYSIO + sofosbuvir
12 weeks simeprevir + sofosbuvir
12 tednov simeprevir
12 weeks therapy
12-tedensko zdravljenje
12 weeks TN (n = 26)
12 tednov predhodno nezdravljeni (n = 26)
12 weeks TN (n = 42)
12 tednov predhodno nezdravljeni (n = 42)
12 weeks treatment duration
12-tedensko 41/41
12 x (1 vial + 1 pre-filled syringe + 1 vial adapter with needle + 2 alcohol wipes)
12 x (1 viala + 1 napolnjena injekcijska brizga + 1 adapter za vialo z iglo + 2 alkoholni blazinici)
12 x (1 vial + 1 pre-filled syringe + 1 vial adapter with needle + 2 alcohol wipes) (Titration pack)
12 x (1 viala + 1 napolnjena injekcijska brizga + 1 adapter za vialo z iglo + 2 alkoholni blazinici) (set za titriranje)
12 x 1 orodispersible tablet: EU/1/09/551/017
12 x 1 orodisperzibilna tableta: EU/1/09/551/017
12 x 1 orodispersible tablet: EU/1/09/551/022
12 x 1 orodisperzibilna tableta: EU/1/09/551/022
12 x 1 orodispersible tablet: EU/1/09/551/027
12 x 1 orodisperzibilna tableta: EU/1/09/551/027
12 x 10 ml (12 x 10 doses)
12 x 10 ml (12 x 10 odmerkov)
12 x 100 ml (12 x 100 doses)
12 x 100 ml (12 x 100 odmerkov)
12 x 250 ml (12 x 250 doses)
12 x 250 ml (12 x 250 odmerkov)
12 x 50 ml (12 x 50 doses)
12 x 50 ml (12 x 50 odmerkov)
12 years -
12 let
12 years and 28 patients aged 13 to 17 years) receiving amlodipine between 1.25 and 20 mg given either once or twice daily.
Farmakokinetično populacijsko študijo so izvedli pri 74 hipertenzivnih otrocih, starih od 1 do 17 let (34 bolnikov je bilo starih od 6 do 12 let in 28 bolnikov starih od 13 do 17 let), ki so prejemali med 1.25 in 20 mg amlodipina enkrat oziroma dvakrat dnevno.
12 ± 2 days
12 ± 2 dni
12 – 24 months booster
Poživitveno cepljenje po 12 mesecih
12 – 24 months booster 71.6% 65.7% 77.5% 70.8%
poživitveno cepljenje po 12 do 24 mesecih
12% (n = 157)
12 % (n = 207)
12% (n = 207)
12 % (n = 158)
12% w/v solution
12% w/v raztopina
12, 24 or 48 weeks SMV in combination with 48 weeks peg-IFN-alfa + RBV;
12, 24 ali 48 tednov SMV v kombinaciji peg-IFN-alfa + RBV, 48 tednov; kontrolna skupina: 48 tednov placebo
12- weeks
V 12.
12-15 yrs old
12-15 let
12-16 hours
12–16 ur
12-23 months
12-23 mesecev
12-23 months4
12-23 mesecev4
12-<18 years N=23
12-< 18 let
12-<18 years N=23
12-< 18 ára N=23
12-month graft survival was 85.3% for Advagraf and 85.6% for Prograf.
Pri uporabi zdravila Advagraf je bilo 12-mesečno preživetje presadka 85,3- odstotno, pri uporabi zdravila Prograf pa 85,6-odstotno.
12-month graft survival was 91.5% for Advagraf and 92.8% for Prograf.
Pri uporabi zdravila Advagraf je bilo 12-mesečno preživetje presadka 91,5-odstotno, pri uporabi zdravila Prograf pa 92,8-odstotno.
12-month graft survival was 96.7% for Advagraf, 92.9% for Prograf and 95.7% for ciclosporin.
Pri uporabi zdravila Advagraf je bilo 12-mesečno preživetje presadka 96,7-odstotno, pri uporabi zdravila Prograf 92,9-odstotno, pri uporabi ciklosporina pa 95,7-odstotno.
12-month treatment arm
kupina z 12-mesečnim zdravljenjem
12-Week
12-tedenske študije
12-week arm
12-tedenska skupina
12-week PFS rate% (95% CI)
12-tedenska stopnja preživetja brez napredovanja bolezni v % (95-odstotni IZ)
12.
Pogosti
12.
ŠKATLA
12.0
ARROW
12.1
vrednost p
12.1 months
12,1 meseca
12.2 (6.2-ne)
12,2 (6,2–no)
12.2 mm x 6.7 mm, ellipse-shaped, normal convex, white film-coated tablets debossed “OZ 15” on one side and “G” on the other side.
12,2 mm x 6,7 mm, ovalne, obojestransko izbočene, bele filmsko obložene tablete z vtisnjeno oznako “OZ 15” na eni strani in “G” na drugi strani.
12.3 (10.4-18.8) (3-week schedule)
12,3 (10,4-18,8) (3-tedenski urnik)
12.34mm x 6.10mm oblong shaped, green tablets debossed with ‘4MG’ on one side and ‘503’ on the other side.
Ovalne, zelene tablete, velike 12,34 mm x 6,10 mm, z vtisnjenim napisom ‘4MG’ na eni strani in ‘503’ na drugi strani.
12.34mm x 6.10mm oblong shaped, white to off-white tablets debossed with ‘2MG’ on one side and “503” on the other side.
Ovalne, bele do belkaste tablete, velike 12,34 mm x 6,10 mm, z vtisnjenim napisom ‘2MG’ na eni strani in ‘503’ na drugi strani.
12.4% vs 2.1%
12,4 % v prim. z 2,1
12.5 % of patients in combination regimens in controlled studies.
Pri zdravilu Viramune se je v nadzorovanih študijah s kombiniranim načinom zdravljenja pojavil pri 12,5 % bolnikov.
12.5 % of patients in combination regimens in controlled studies.
V nadzorovanih študijah s kombiniranim načinom zdravljenja se je pojavil pri 12,5 % bolnikov.
12.5 hours after the evening dose the day before, and therefore 30 minutes after the following morning dose is given.
30 minut po zaužitju naslednjega jutranjega odmerka.
12.5 mg daily), the antihypertensive response in black patients approaches that of non-black patients.
12,5 mg na dan), se antihipertenzivni učinek pri temnopoltih bolnikih približa učinku pri netemnopoltih bolnikih.
12.5 mg daily), the antihypertensive response in black patients approaches that of white patients.
12,5 mg dnevno), se antihipertenzivni odziv temnopoltih bolnikov z visokim krvnim tlakom približa odzivu belcev.
12.5 mg daily), the antihypertensive response in black patients approaches that of white patients.
12,5 mg/dan), se njihov antihipertenzivni odziv približa odzivu belcev.
12.5 mg dose, and these reductions were considered clinically relevant.
Ti zmanjšanji sta bili klinično pomembni.
12.5 mg hard capsules
12,5 mg trde kapsule
12.5 mg/1,000 mg combination tablets are bioequivalent to co-administration of corresponding doses of empagliflozin and metformin as individual tablets.
12,5 mg/850 mg in 12,5 mg/1.000 mg bioekvivalentne sočasno danim posamičnim tabletam empagliflozina in metformina v enakih odmerkih.
12.5 mg/kg bw
12,5 mg/kg tel. mase
12.5 ml is made up of a 5 ml dose plus a 7.5 ml dose
12,5 ml lahko pripravite iz 5-ml odmerka in 7,5-ml odmerka
12.5 ml once daily
12.5 ml enkrat na dan
12.5 ml twice daily
12.5 ml dvakrat na dan
12.5 mm x 8.0 mm, green, film-coated, oval, biconvex, bevelled edge tablet debossed with M on one side of the tablet and CI60 on the other side.
Zelena, ovalna, bikonveksna filmsko obložena tableta z zglajenim robom, dimenzij 12,5 mm x 8,0 mm z vtisnjeno oznako "M" na eni strani in "CI60" na drugi strani.
12.6 mg per pre-filled syringe) if the PEG moiety and the carbohydrate linker are included.
12,6 mg na napolnjeno injekcijsko brizgo), če sta vključena tudi PEG in vezni ogljikov hidrat.
12.66]
Liraglutid (mg)
12.MARKETING AUTHORISATION NUMBER(S)
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
120 (10 x 12) tablets
120 tablet
120 (2 x 60 x 1) tablets
120 (2 x 60 x 1) tablet
120 (2 x 60 x 1) tablets (unit
120 (2 x 60 x 1) tablet
120 (2 x 60) capsules (multipack)
120 (2 x 60) kapsul (skupno pakiranje)
120 (2 x 60) tablets
120 (2 x 60) tablet
120 (2x60) tablets (multipack)
120 (2x60) tablet (skupno pakiranje)
120 capsules
120 kapsule
120 chewable tablets
120 žvečljivih tablet
120 Elisa Units CSF E2 antigen/2ml.
120 Elisa enot antigena KPK E2/2 ml
120 film-coated tablets
120 filmsko obloženimi
120 film-coated tablets
Steklenička 120 filmsko obloženih
120 mg (6 ml) once daily
120 mg (6 ml) enkrat dnevno
120 mg gastro-resistant hard capsules: 4 years 240 mg gastro-resistant hard capsules: 4 years
120 mg gastrorezistentne trde kapsule: 4 leta 240 mg gastrorezistentne trde kapsule: 4 leta
120 mg twice a day.
120 mg dvakrat na dan.
120 mg VIAL LABEL
120 mg NALEPKA VIALE
120 mg yellow, ovaloid tablets with “NVR” marked on one side and “TSL” on the other.
120 mg rumene, ovalne tablete z oznako “NVR” na eni ter “TSL” na drugi strani.
120 mg yellow, ovaloid tablets with “STARLIX” marked on one side and “120” on the other.
120 mg rumene, ovalne tablete z oznako “STARLIX” na eni ter “120” na drugi strani.
120 mg/kg/day, with estimated exposure multiples of 3 to 75 times, based on a human daily sublingual dose of 16 mg calculated on a mg/m² basis.
120 mg/kg/dan z ocenjenim večkratnim faktorjem od 3 do 75-krat za izpostavljenost pri ljudeh na osnovi dnevnega podjezičnega odmerka 16 mg, izračunanega na osnovi mg/m².
120 micrograms PRE-FILLED SYRINGES LABEL
NALEPKA ZA NAPOLNJENO INJEKCIJSKO BRIZGO 120 mikrogramov
120 mL solution, in an amber-glass bottle fitted with a low density polyethylene insert and a child resistant polypropylene screw cap, provided with a polypropylene oral syringe graduated in mg of propranolol base.
120 ml raztopina v rjavorumeni steklenici, opremljeni z vložkom iz polietilena nizke gostote in za otroke varno polipropilensko navojno zaporko, priložena je polipropilenska peroralna brizga, umerjena v miligramih propranolola.
120 mL/min), suggesting some active renal excretion.
120 ml/min), kar kaže na delno aktivno izločanje preko ledvic.
120 Patients were randomised to a modified XELIRI regimen with capecitabine 800 mg/m2 twice daily for two weeks followed by a 7-day rest period), irinotecan (200 mg/m2 as a 30 minute infusion on day 1 every 3 weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks ;
Randomizirali so 120 bolnikov v spremenjeno shemo XELIRI: kapecitabin (800 mg/m2 dvakrat na dan dva tedna, čemur je sledil 7-dnevni premor), irinotekan (200 mg/m2 v 30-minutni infuziji 1. dan vsake 3 tedne) in bevacizumab (7,5 mg/kg v 30 do 90-minutni infuziji 1. dan vsake 3 tedne).
120 soft capsules
120 mehkih kapsul
120 sprays
120 vpihov
120 tablets
120 filmsko obloženih tablet
120 tablets
120 tablete
120 tablets
14 tablet
120 tablets.
120 tablet
120 tablets: EU/1/09/579/004
120 tablet: EU/1/09/579/004
120 tablets: EU/1/09/579/010
120 tablet: EU/1/09/579/010
120 tablets: EU/1/09/579/016
120 tablet: EU/1/09/579/016
120 tablets: EU/1/09/580/004
120 tablet: EU/1/09/580/004
120 tablets: EU/1/09/580/010
120 tablet: EU/1/09/580/010
120 tablets: EU/1/09/580/016
120 tablet: EU/1/09/580/016
120 to 139.9 kg
120 do 139,9 kg
120 x 1
120 x 1 kapsul
120 x 1 film-coated tablets
120 x 1 filmsko obložena tableta
120 x 1 film-coated tablets
120 x 1 filmsko obloženih tablet
120 x 1 tablets
120 x 1 tablet
120 x 1 tablets (unit dose)
120 x 1 tablet (enoodmernih pretisnih)
1200
1200 kalorij
1200 IU
1200 i.e.
1200 IU (87 g)/vial
1 200 i.e. (87 μg)/vialo
1200 IU*** human von Willebrand factor** (VWF)
1200 i.e.*** humanega von Willebrandovega faktorja** (VWF).
1200 IU*** human von Willebrand factor** (VWF).
1200 i.e.*** humanega von Willebrandovega faktorja** (VWF).
1200 mg tid)
1200 mg trikrat na dan)
1200 to 1600 mg (duration varying between 1 to 10 days): Nausea, vomiting, diarrhoea, rash, erythema, oedema, swelling, fatigue, muscle spasms, thrombocytopenia, pancytopenia, abdominal pain, headache, decreased appetite.
Odmerki od 1200mg do 1600 mg (trajanje zdravljenja od 1 do 10 dni): navzea, bruhanje, driska, izpuščaj, eritem, edemi, otekanje, utrujenost, mišični spazmi, trombocitopenija, pancitopenija, bolečine v trebuhu, glavobol, zmanjšan tek.
1206 paediatric patients aged 3 months to 17 years enrolled in the ARROW Trial (COL105677) and were dosed according to the weight - band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006).
1206 pediatričnih bolnikov, starih od 3 mesece do 17 let, so vključili v preskušanje ARROW (COL105677) in so prejemali odmerke v skladu z odmernimi priporočili glede na telesno maso po terapevtskih smernicah Svetovne zdravstvene organizacije (Protiretrovirusno zdravljenje okužbe s HIV pri dojenčkih in otrocih, 2006).
121 (38)b
CR+nCR+PR+M R
121 weeks), including 3 patients ambulatory and 3 patients with only functional sitting skills by the last study visit.
3 ambulantnimi bolniki in 3 bolniki s samo funkcionalno sposobnostjo sedenja do zadnjega obiska v študiji.
1210 Vienna AUSTRIA
1210 Dunaj AVSTRIJA
1211 Vienna Austria
1211 Vienna Avstrija
122 (0.80)
vred- nost p
1221 Vienna Austria
1221 Dunaj Avstrija
123 51 Athens, Greece
123 51 Athens, Grčija
123 51 Athens, Greece.
123 51 Athens, Grčija
123 [69, 221]
Smrtne
123 days
123 dni
1236 Trzin Slovenia
1236 Trzin Slovenija
12489 Berlin Germany
12489 Berlin Nemčija
125 (12 MIU), and 188 (18 MIU) micrograms respectively, compared to intramuscular administration of 30 (6 MIU) micrograms non-pegylated beta-1a.
188 (18 milijonov i.e.) mikrogramov, v primerjavi z intramuskularnim dajanjem 30 (6 milijonov i.e.) mikrogramov nepegiliranega beta-1a.
125 doses
125 od- merkov